Look for Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. in New Orleans at the American Association for Cancer Research (AACR) Annual Meeting 2022 through Wednesday, April 13th. He will be catching up on the latest advances in cancer science and medicine. The AACR Annual Meeting highlights the work of the best minds...
Immunophotonics continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug candidate, IP-001. The latest financing tranche, which was raised through the sale of the company’s authorized Series B Preferred Stock, has yielded $21.4 million in investments. Read More
Lu Alleruzzo, CEO; Tomas Hode, CIO & President; and the Immunophotonics Team want to congratulate Dr. Wei Chen on being elected to the American Institute of Medical and Biological Engineering (AIMBE) College of Fellows for his outstanding contributions to the invention, development, translation, and commercialization of laser immunotherapy for the treatment of metastatic cancers. This...
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the SIO 2022 annual scientific meeting March 24 – 28 in San Francisco, California. He connected with interventional oncology professionals and learned about the developments in cancer therapy worldwide alongside medical, surgical and radiation oncology.
Lu Alleruzzo co-founder and CEO of Immunophotonics attended the NYSE 9th Annual 2022 IPO Summit. Very inspiring to hear from senior executives and advisors from some high-profile IPO’s and SPACs and how companies are entering the public market. 2022 is proving to be very exciting for Immunophotonics.
The continued success of Immunophotonics is driven by the dedication and hard work of our team. Immunophotonics was one of 11 dealmakers honored on March 4th at the 2022 St. Louis Dealmakers Conference. Smart Business Dealmakers was created by the Smart Business Dealmakers Institute to serve as a resource for news, insights, and networking for...
Immunophotonics, Inc. was recently awarded a Small Business Innovative Research (SBIR) Phase I and Phase II Fast-Track grant for research regarding use of the company’s lead drug candidate, IP-001 by the NIH’s National Cancer Institute. This research will be conducted by Immunophotonics Inc and its collaborators at the University of Louisville Division of Surgical Oncology....
Hot off the press: Another part of the mechanism of action of how IP-001 (GC) remodels the tumor microenvironment revealed! Check out this key publication to understand how tumor ablation paired with IP-001 influences B cell activation, its role in extending survival, and the favorable clinical implications. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692917/pdf/thnov12p0639.pdf
If you are interested in the interface between cancer immunotherapy innovation and photonics, then catch up with Tomas Hode, PhD, co-founder, CIO, and President of Immunophotonics, Inc. in person at SPIE, the international society for optics and photonics conferences #PhotonicsWest / #BiOS 2022 Jan 22 – 27 in San Francisco. He and Lu Alleruzzo (CEO)...
Immunophotonics is pleased to announce that the United States Patent and Trademark has issued U.S. Patent No. 11111316, which covers the composition of matter of its proprietary synthetic biopolymer, IP-001. Immunophotonics is currently conducting clinical studies for the use of IP-001 to treat various metastatic cancer indications and is exploring other applications of the drug...
